Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting

<p>SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting/">Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>